Fri, May 8, 2009
Thu, May 7, 2009
Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009
Mon, April 13, 2009
Fri, April 10, 2009
Thu, April 9, 2009
Wed, April 8, 2009
Tue, April 7, 2009
Mon, April 6, 2009
Fri, April 3, 2009
Thu, April 2, 2009
Wed, April 1, 2009
Tue, March 31, 2009
Mon, March 30, 2009
Fri, March 27, 2009
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009

Electro-Optical Sciences, Inc.: Electro-Optical Sciences Announces Participation at the Cowen and Company 29th Annual Health Ca


//health-fitness.news-articles.net/content/2009/ .. the-cowen-and-company-29th-annual-health-ca.html
Published in Health and Fitness on Monday, March 9th 2009 at 6:40 GMT, Last Modified on 2009-03-09 06:40:54 by Market Wire   Print publication without navigation


IRVINGTON, NY--(Marketwire - March 9, 2009) - Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: [ MELA ]), a medical device company focused on the design and development of MelaFind®, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, today announced that Joseph V. Gulfo, MD, president and chief executive officer, will present at the Cowen and Company 29th Annual Health Care Conference taking place at the Boston Marriott Copley Place on March 16 - 19, 2009.

Dr. Gulfo's presentation is scheduled for Monday, March 16 at 2:25pm ET. To access the live webcast of this presentation, visit [ www.eosciences.com ]. A replay of this presentation will be available on the company's website for thirty days following the presentation.

About Electro-Optical Sciences

EOS is a medical device company focused on designing and developing a non-invasive, point-of-care instrument to assist in the early detection of melanoma. MelaFind features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. The data are then analyzed utilizing imaging processing classification algorithms, trained on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient, including information useful in the decision of whether to biopsy the lesion.

Melanoma is the deadliest of skin cancers, responsible for approximately 80% of all skin cancer deaths. Unless melanoma is detected early and excised with proper margins, the patient survival rate is poor, as there is currently no cure for advanced stage melanoma.

For more information on EOS, visit [ www.eosciences.com ].

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors.


Publication Contributing Sources

Similar Health and Fitness Publications